Compare IDEXX Laboratories, Inc. (IDXX) vs Petróleo Brasileiro SA (PBR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Petróleo Brasileiro SA — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while Petróleo Brasileiro SA trades at $25.3 (market cap $151.94B). The key difference: Petróleo Brasileiro SA is far larger — about 3.8× IDEXX Laboratories, Inc.'s market cap, and Petróleo Brasileiro SA pays a 6.79% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Petróleo Brasileiro SA for 25 Days on average.
| IDXX | PBR | |
|---|---|---|
Market Cap | $40.43B | $151.94B |
Volume | 692,164 | 30,240,092 |
Sector | Health | Energy |
52-Week High | $766.68 | $25.30 |
52-Week Low | $504.70 | $11.54 |
Typical Hold Time | 46 Days | 25 Days |
Enterprise Value | $41.32B | $212.36B |
Dividend Yield | — | 6.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $4.27 exceeding the $3.94 estimate. Revenue grew to $4.3 billion in 2025, and net income margin expanded to 25.03%. Recent acquisitions like CoVetAI aim to enhance veterinary workflow intelligence.
The outlook remains positive given robust profitability and analyst consensus, but risks include foreign exchange headwinds and competitive pressures. With a consensus price target of $665, representing ~30% upside, the stock offers growth potential for investors comfortable with its premium valuation multiples.
Petrobras (PBR) trades at $24.69, up 2.92% with strong bullish momentum. The stock shows robust fundamentals with a low P/E of 6.24, ROE of 30.77%, and consistent earnings beats. Recent developments include new oil discoveries and LNG supply agreements, while technical indicators show overbought conditions with RSI above 80. Analyst consensus leans bullish with 50% buy ratings.
PBR offers compelling value with strong profitability and growth prospects, though elevated RSI suggests near-term consolidation risk. The company's expansion projects and dividend policy support long-term upside, but investors should monitor oil price volatility and Brazilian political factors that could impact operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →
